AIRLINK 58.94 Increased By ▲ 0.95 (1.64%)
BOP 6.22 No Change ▼ 0.00 (0%)
CNERGY 4.03 Decreased By ▼ -0.02 (-0.49%)
DFML 15.90 Increased By ▲ 0.20 (1.27%)
DGKC 68.80 Increased By ▲ 0.25 (0.36%)
FCCL 17.70 Decreased By ▼ -0.05 (-0.28%)
FFBL 26.00 Increased By ▲ 0.25 (0.97%)
FFL 9.24 Decreased By ▼ -0.07 (-0.75%)
GGL 10.03 Increased By ▲ 0.29 (2.98%)
HBL 111.85 Increased By ▲ 0.05 (0.04%)
HUBC 115.40 Increased By ▲ 0.60 (0.52%)
HUMNL 6.50 Increased By ▲ 0.06 (0.93%)
KEL 4.27 Decreased By ▼ -0.03 (-0.7%)
KOSM 3.65 Increased By ▲ 0.07 (1.96%)
MLCF 37.55 Increased By ▲ 0.15 (0.4%)
OGDC 117.78 Increased By ▲ 0.58 (0.49%)
PAEL 22.80 Decreased By ▼ -0.10 (-0.44%)
PIAA 11.15 Decreased By ▼ -0.20 (-1.76%)
PIBTL 5.90 Increased By ▲ 0.23 (4.06%)
PPL 104.55 Decreased By ▼ -0.70 (-0.67%)
PRL 26.60 Increased By ▲ 0.05 (0.19%)
PTC 9.70 Increased By ▲ 0.10 (1.04%)
SEARL 51.82 Decreased By ▼ -1.52 (-2.85%)
SNGP 65.11 Increased By ▲ 0.12 (0.18%)
SSGC 11.03 Increased By ▲ 0.09 (0.82%)
TELE 7.27 Increased By ▲ 0.11 (1.54%)
TPLP 11.90 Increased By ▲ 0.03 (0.25%)
TRG 75.14 Increased By ▲ 2.43 (3.34%)
UNITY 20.60 Decreased By ▼ -0.13 (-0.63%)
WTL 1.29 Decreased By ▼ -0.02 (-1.53%)
BR100 6,311 Increased By 25.1 (0.4%)
BR30 21,641 Increased By 55 (0.25%)
KSE100 61,802 Increased By 242.4 (0.39%)
KSE30 20,792 Increased By 73.8 (0.36%)

GENEVA: A World Health Organization technical body said on Tuesday that current COVID-19 vaccines may need to be reworked to ensure they are effective against Omicron and future variants of the coronavirus.

The technical group, made up of independent experts, said it would consider a change in vaccination composition and stressed that shots needed to be more effective in protecting against infection.

"The composition of current COVID-19 vaccines may need to be updated to ensure that COVID-19 vaccines continue to provide WHO-recommended levels of protection against infection and disease by VOCs (variants of concern), including Omicron and future variants," the technical body, tasked with making recommendations to the WHO, said in a statement.

"COVID-19 vaccines need to...elicit immune responses that are broad, strong, and long-lasting in order to reduce the need for successive booster doses," it added.

"A vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable."

Over 50% of Europeans on track to contract Omicron: WHO

However, the statement stopped short of advocating an Omicron-specific vaccine at this stage, saying more research was required and urging manufacturers to share data.

It said that an updated vaccine could be aimed specifically at the dominant variant, which is currently Omicron in many places, or be a "multivalent vaccine" designed to bust several variants at once. Further recommendations will be issued when more data is available, it added.

Some vaccine makers are already developing next-generation vaccines targeting Omicron, the highly contagious variant first detected in southern Africa and Hong Kong.

On Monday, Pfizer Chief Executive Albert Bourla said a redesigned COVID-19 vaccine that specifically targets the Omicron variant would probably be needed and his company could have one ready to launch by March.

Rival Moderna Inc is also working on a vaccine candidate tailored to Omicron, but it is unlikely to be available in the next two months.

A WHO official had previously said the issue of vaccine composition required "global coordination" and should not be left to manufacturers to decide alone.

Comments

Comments are closed.